Barclays maintains Bausch Health Companies at Equal-Weight, raises price target to $9 from $7

Barclays kept Bausch Health Companies at Equal-Weight, raising its price target to $9 from $7, a 28.6% increase. This implies a 23.6% downside from the Nov 10 close of $11.78.

Original reporting
Published Nov 11, 2026, 3:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Bausch Health Companies at Equal-Weight, raises price target to $9 from $7 — source image
Decision brief

The 30-second read

$BHCBearishMed
01

Why it matters

The downgrade may trigger short‑term selling pressure, especially among momentum traders.

02

Market read

A modest analyst downgrade that could influence short‑term price action but is unlikely to drive sector‑wide moves.

03

What to watch

Potential upcoming product launches or cost‑cutting measures that could improve earnings were not discussed.

Relevance 6/10Novelty 6/10Timing: today

Background

Barclays' analyst team adjusted its valuation model for Bausch Health Companies, reflecting recent performance and outlook.

Company-level read

Ticker impact

$BHCBearishMedium confidence
Context

Barclays raised its price target for Bausch Health Companies to $9 from $7, implying a downside from the current price.

Expected impact

likely pressure as investors adjust expectations to the lower target

Evidence & confidence

The new target is below the recent close, indicating reduced upside and potential sell‑off.

Market effects

Minimal; the change is specific to Bausch Health and does not signal broader sector shifts.

Limited to U.S. and Canadian investors tracking the stock.

Low; the news is company‑specific without global macro implications.

Counterpoint

Some investors may view the lower target as an opportunity if they believe the market has over‑reacted to recent volatility.

Key entities

  • Barclays

    Equity research firm that issued the price target change.

  • Bausch Health Companies

    Pharmaceutical firm whose stock is affected by the target revision.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.